2022 World Conference on Lung Cancer (ePosters)-EP08.01-010. Troponin Elevation and the Risk of Myocarditis among NSCLC Patients Treated with Immune Checkpoint Inhibitors

EP08.01-010. Troponin Elevation and the Risk of Myocarditis among NSCLC Patients Treated with Immune Checkpoint Inhibitors

Back to course

Pdf Summary

This study aimed to assess the value of measuring high sensitivity troponin I (hs-TnI) in predicting cardiovascular outcomes and survival in cancer patients treated with pembrolizumab, an immune checkpoint inhibitor (ICI). The study included 135 patients who had baseline hs-TnI measurements before starting pembrolizumab (T1) and follow-up measurements at their second encounter (T2). The results showed that abnormal elevated hs-TnI at both T1 and T2 were significant independent predictors for major adverse cardiac events (MACE), including myocarditis, acute coronary syndrome, heart failure, venous thromboembolism, cardiovascular hospitalization, and cardiovascular mortality. Abnormal elevated baseline hs-TnI also predicted all-cause mortality. The study found a higher incidence of MACE in patients with abnormal elevated baseline hs-TnI, suggesting that routine measurement of hs-TnI may have a predictive role for future cardiovascular outcomes in patients treated with ICI therapy. The results highlight the potential of hs-TnI as a biomarker for early detection of myocarditis or myocardial injury following ICI exposure. The study emphasizes the importance of monitoring cardiovascular health in cancer patients receiving ICI therapy and suggests the need for larger trials to further evaluate the role of hs-TnI measurement in predicting adverse cardiovascular outcomes.

Asset Subtitle

Barliz Waissengrin

Meta Tag

Speaker Barliz Waissengrin

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

hs-TnI

cardiovascular outcomes

cancer patients

pembrolizumab

MACE

myocarditis

heart failure

biomarker

ICI therapy

myocardial injury